GENFIT
GENFIT, a biopharmaceutical company headquartered in France, is at the forefront of developing innovative therapies for metabolic and liver diseases. Founded in 2008, the company has made significant strides in the industry, particularly with its focus on non-alcoholic steatohepatitis (NASH) and other related conditions. With a robust pipeline of clinical programmes, GENFIT's core products, including its lead candidate elafibranor, are designed to address unmet medical needs in liver health. The company distinguishes itself through its commitment to precision medicine and the integration of advanced biomarkers in its research. Recognised for its expertise, GENFIT has established a strong market position, contributing to the evolving landscape of liver disease treatment. Its dedication to innovation and patient-centric solutions continues to drive its success in the biopharmaceutical sector.
DitchCarbon Score
How does GENFIT's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
GENFIT's score of 38 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
GENFIT's reported carbon emissions
In 2024, GENFIT reported total carbon emissions of approximately 627,000 kg CO2e, with Scope 1 and 2 emissions accounting for about 584,000 kg CO2e and Scope 3 emissions contributing approximately 879,000 kg CO2e. This marks a reduction from 2023, where total emissions were about 756,000 kg CO2e, with Scope 1 and 2 emissions also at approximately 584,000 kg CO2e and Scope 3 emissions at around 804,000 kg CO2e. GENFIT has set ambitious climate commitments, aiming to reduce its Scope 1 and 2 emissions to near zero by 2025. Additionally, the company targets a 45% reduction in Scope 1 emissions by 2030 compared to 2021 levels, as well as a similar 45% reduction in Scope 2 emissions by the same year. These initiatives reflect GENFIT's commitment to addressing its carbon footprint and contributing to climate action. The emissions data is sourced directly from GENFIT S.A., with no cascaded data from parent or related organizations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | - | - | - |
| Scope 2 | - | - | - |
| Scope 3 | 751,000 | 000,000 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
GENFIT is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
